Lingual hyperpigmentation from pegylated interferon and ribavirin treatment of hepatitis C.
Farshidi
Dina
D
Division of Dermatology, David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles, California.
Chiu
Melvin W
MW
Division of Dermatology, David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles, California. Electronic address: mchiu@mednet.ucla.edu.
D000328:Adult; D000998:Antiviral Agents / Q000009:adverse effects* / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D006526:Hepatitis C / Q000188:drug therapy*; D006801:Humans; D017495:Hyperpigmentation / Q000139:chemically induced*; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects* / Q000627:therapeutic use; D011092:Polyethylene Glycols / Q000009:adverse effects* / Q000627:therapeutic use; D011994:Recombinant Proteins; D012254:Ribavirin / Q000627:therapeutic use*; D014060:Tongue Diseases / Q000139:chemically induced*
D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C417083:peginterferon alfa-2b